AstraZeneca preps for EUA application, releases phase 3 U.S. data

by on

AstraZeneca preps for EUA application, releases phase 3 U.S. data
tjordan_drupal
Mar 22, 2021

AstraZeneca today said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients. 

The drug maker said its two-dose candidate is 79% effective in preventing symptomatic COVID-19, with a 100% efficacy against severe or critical disease and hospitalization. Based on its results, AstraZeneca said it would formally apply for an emergency use authorization with the Food and Drug Administration.
 

 

Headline

AstraZeneca preps for EUA application, releases phase 3 U.S. data
tjordan_drupal
Mar 22, 2021

AstraZeneca today said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients. 

The drug maker said its two-dose candidate is 79% effective in preventing symptomatic COVID-19, with a 100% efficacy against severe or critical disease and hospitalization. Based on its results, AstraZeneca said it would formally apply for an emergency use authorization with the Food and Drug Administration.
 

 

Novel Coronavirus (SARS-CoV-2/COVID-19)
COVID-19: Vaccines and Therapeutics

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: